|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | Uveitis ≥1 during the first TNF inhibitor | | |  |  | Uveitis ≥1 during all TNF inhibitor lines | | |
|  |  | Yes | No | p |  |  | Yes | No | p |
| Uveitis ≥1 before TNF inhibitor | Yes | 25 | 48 | 0.0002 | *Uveitis ≥1 before TNF inhibitor* | Yes | 6 | 67 | 0.049 |
| No | 17 | 311 | No | 46 | 282 |

Supplementary table S2: Qualitative analysis of the occurrence of at least 1 uveitis before and during TNF inhibitor treatment in patients with SpA or PsA

SpA : spondyloarthritis ; PsA : psoriatic arthritis